RegeneRx

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

April 28, 2016
RegeneRx and ReGenTree Expand License for Dry Eye


April 6, 2016
RegeneRx to Receive EU Patent for Use of Tβ4 in Preventing And Treating Damage Associated with Reperfusion Injury


March 14, 2016
Rodman & Renshaw Initiates Coverage of RegeneRx Biopharmaceuticals, Inc. with Buy Rating


February 1, 2016
RegeneRx Meeting with Institutional Investors and Analysts At BIO CEO Conference


January 29, 2016
RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial